Efficacy of single dose of oral mizoribine pulse therapy two times per week for frequently relapsing nephrotic syndrome

Journal of Nephrology

Volumn 20, Issue 1, 2007, Pages 52-56

  Kawasaki, Yukihiko ^a,e   Takano, Kei ^a   Isome, Masato ^a   Suzuki, Junzo ^a   Suyama, Kazuhide ^b   Kanno, Hiroyuki ^c   Fujiki, Tomoo ^d   Suzuki, Hitoshi ^a   Hosoya, Mitsuaki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Department of Pediatrics   (Japan)

^c Futaba General Hospital   (Japan)

^d Takeda General Hospital   (Japan)

^e NONE   (Japan)

Author keywords

Children; Frequently relapsing nephrotic syndrome; Oral mizoribine pulse therapy

Indexed keywords

MIZORIBINE; PREDNISOLONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; RIBONUCLEOSIDE;

ACIDEMIA; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MALE; NEPHROTIC SYNDROME; RECURRENT DISEASE; RELAPSE; SINGLE DRUG DOSE; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME; PREDNISOLONE; PULSE THERAPY, DRUG; RECURRENCE; RIBONUCLEOSIDES;

EID: 34447278844     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 1996; 36: 1081-92.
2. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S; for the Pediatric Mizoribine Study Group in Japan. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 2000; 58; 317-24.
3. Ohtomo Y, Fujinaga S, Takada M, Murakami H, Akashi S, Shimuzu T, Kaneko K, Yamashiro Y. High-dose mizoribine therapy for childhood-onset frequently relapsing steroid-dependent nephritic syndrome with cyclosporin nephrotoxicity. Pediatr Nephrol 2005; 20: 1744-9.
4. Kawasaki Y, Suzuki J, Takahashi A, Isome M, Nozawa R, Suzuki H. Mizoribine oral pulse therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005; 20: 96-8.
5. Kawasaki Y, Hosoya M, Kobayashi S, Ohara S, Onishi N, Takahashi A, Isome M, Suzuki H. Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid- dependent nephrotic syndrome. Nephrol Dial Transplant 2005; 20: 2243-7.
6. Tanaka H, Tsugawa K, Nakahata T, Kudo M, Onuma SI, Kimura S, Ito E. Mizoribine pulse therapy for a patient with steroid-resistant nephrotic syndrome. Tohoku J Exp Med 2005; 205: 87-91.
7. Nievergelt Y. UMAP module 718: splines in single and multivariable calculus. Lexington, MA: COMAP 1993.
8. Mendoza SA, Tune BM. Management of the difficult nephritic patient. Pediatr Clin North Am 1995; 42: 1459-68.
9. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5: 1820-5.
10. Gregory MJ, Smoyer WE Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 1996; 7: 543-9.
11. Durkan AM, Hodson EM, Willis NS, Craig JC. Immunosuppressive agents in childhood nephrotic syndrome: a metaanalysis of randomized controlled trials. Kidney Int 2001; 59: 1919-27.
12. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 2000; 274: 87-92.